Pamlab LLC Release: Breakthrough Study Shows Benefits of Adjunctive L-methylfolate in the Treatment of SSRI-Resistant Major Depressive Disorder

Published: Dec 18, 2012

COVINGTON, La.--(BUSINESS WIRE)--New research shows that patients with SSRI-resistant depression can benefit from augmentation therapy with the medical food L-methylfolate. The study, published in the American Journal of Psychiatry, demonstrates the safety superior response and tolerability of L-methylfolate, (available by prescription in the U.S. under the brand name Deplin®) in patients with Major Depressive Disorder (MDD). Approximately two thirds of people living with depression will be unsuccessful with their first round of antidepressant monotherapy. Yet, many are unaware that certain metabolic imbalances inhibit adequate response to treatment with traditional serotonin reuptake inhibitors (SSRI’s) alone.

Back to news